Myriad Genetics, Inc. (MYGN) is making notable strides in its key strategic areas, which is poised to help it grow in the upcoming quarters. New product introductions and enhancements are gaining traction with customers. There is growing optimism about the company’s huge potential in the oncology space. Meanwhile, the impacts of macroeconomic pressure and fierce rivalry can be worrisome for Myriad Genetics’ performance.In the past year, this Zacks Rank #3 (Hold) company has outperformed both the industry an ...